Jing-Yuan Xu1, Wei Chang1, Qin Sun1, Fei Peng1, Yi Yang2. 1. Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, 87 Dingjiaqiao Rd., Nanjing, 210009, People's Republic of China. 2. Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, 87 Dingjiaqiao Rd., Nanjing, 210009, People's Republic of China. yiyiyang2004@163.com.
Abstract
BACKGROUND: Midkine is a multi-functional molecule participating in a various key pathological process. We aimed to evaluate the change of midkine in sepsis and its association with angiotensin-converting enzyme (ACE) system, as well as the mechanism by which midkine induced in sepsis and lung injury. METHODS: The peripheral blood sample of septic patients on admission was obtained and measured for midkine, ACE and angiotensin II. Cecal ligation and puncture (CLP) mouse model was used, and adeno-associated virus (AAV) was stilled trans-trachea for regional targeting midkine expression, comparing the severity of lung injury. Furthermore, we studied the in vitro mechanism of midkine activates ACE system by using inhibitors targeting candidate receptors of midkine, and its effects on the vascular endothelial cells. RESULTS: Plasma midkine was significantly elevated in sepsis, and was closely associated with ACE system. Both circulating and lung midkine was increased in CLP mouse, and was related to severe lung injury. Regional interfering midkine expression in lung tissue by AAV could alleviate acute lung injury in CLP model. In vitro study elucidated that Notch 2 participated in the activation of ACE system and angiotensin II release, induced by midkine and triggered vascular endothelial injury by angiotensin II induced reactive oxygen species production. CONCLUSIONS: Midkine inhibition ameliorates sepsis induced lung injury, which might via ACE/Ang II pathway and the participation of Notch 2 in the stimulation of ACE. Trial registration Clinicaltrials.gov NCT02605681. Registered 12 November 2015.
BACKGROUND:Midkine is a multi-functional molecule participating in a various key pathological process. We aimed to evaluate the change of midkine in sepsis and its association with angiotensin-converting enzyme (ACE) system, as well as the mechanism by which midkine induced in sepsis and lung injury. METHODS: The peripheral blood sample of septicpatients on admission was obtained and measured for midkine, ACE and angiotensin II. Cecal ligation and puncture (CLP) mouse model was used, and adeno-associated virus (AAV) was stilled trans-trachea for regional targeting midkine expression, comparing the severity of lung injury. Furthermore, we studied the in vitro mechanism of midkine activates ACE system by using inhibitors targeting candidate receptors of midkine, and its effects on the vascular endothelial cells. RESULTS: Plasma midkine was significantly elevated in sepsis, and was closely associated with ACE system. Both circulating and lung midkine was increased in CLPmouse, and was related to severe lung injury. Regional interfering midkine expression in lung tissue by AAV could alleviate acute lung injury in CLP model. In vitro study elucidated that Notch 2 participated in the activation of ACE system and angiotensin II release, induced by midkine and triggered vascular endothelial injury by angiotensin II induced reactive oxygen species production. CONCLUSIONS:Midkine inhibition ameliorates sepsis induced lung injury, which might via ACE/Ang II pathway and the participation of Notch 2 in the stimulation of ACE. Trial registration Clinicaltrials.gov NCT02605681. Registered 12 November 2015.
Authors: Cenap Güngör; Hilke Zander; Katharina E Effenberger; Yogesh K Vashist; Tatyana Kalinina; Jakob R Izbicki; Emre Yekebas; Maximilian Bockhorn Journal: Cancer Res Date: 2011-06-01 Impact factor: 12.701
Authors: Ludwig T Weckbach; Leopold Groesser; Julia Borgolte; Judith-Irina Pagel; Frank Pogoda; Jürgen Schymeinsky; Josef Müller-Höcker; Mehdi Shakibaei; Takashi Muramatsu; Elisabeth Deindl; Barbara Walzog Journal: Am J Physiol Heart Circ Physiol Date: 2012-06-15 Impact factor: 4.733
Authors: Rong Zhang; Ying Pan; Vito Fanelli; Sulong Wu; Alice Aili Luo; Diana Islam; Bing Han; Pu Mao; Mirna Ghazarian; Wenmei Zeng; Peter M Spieth; Dingyan Wang; Julie Khang; Hongyin Mo; Xiaoqing Liu; Stefan Uhlig; Mingyao Liu; John Laffey; Arthur S Slutsky; Yimin Li; Haibo Zhang Journal: Am J Respir Crit Care Med Date: 2015-08-01 Impact factor: 21.405
Authors: Tao Rui; Qingping Feng; Ming Lei; Tianqing Peng; Jianhua Zhang; Ming Xu; E Dale Abel; Anargyros Xenocostas; Peter R Kvietys Journal: Cardiovasc Res Date: 2005-02-15 Impact factor: 10.787
Authors: Hong Zhang; Patrick Neuhöfer; Liang Song; Björn Rabe; Marina Lesina; Magdalena U Kurkowski; Matthias Treiber; Thomas Wartmann; Sara Regnér; Henrik Thorlacius; Dieter Saur; Gregor Weirich; Akihiko Yoshimura; Walter Halangk; Joseph P Mizgerd; Roland M Schmid; Stefan Rose-John; Hana Algül Journal: J Clin Invest Date: 2013-02-15 Impact factor: 14.808